TS

The financial and operational information contained in this press release is based on unaudited consolidated condensed interim financial statements presented in U.S. dollars and prepared in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board and adopted by the European Union, or IFRS. Additionally, this press release includes non-IFRS alternative performance measures i.e., EBITDA, Free cash flow, Net cash / (debt) and Operating working capital days. See exhibit I for more details on these alternative performance measures.

Tenaris is rated 'HOLD' with a price target of €16/share ($36.91 ADR), reflecting cyclical risks and recent overvaluation. TS faces near-term headwinds from Hormuz shipment delays, margin compression, and declining revenues, signaling a mid-cycle to early downcycle transition. While TS maintains a strong balance sheet and leading market position, its earnings power remains tightly linked to volatile energy CapEx cycles.

Tenaris S.A. (TS) Q2 2026 Earnings Call Transcript

The financial and operational information contained in this press release is based on unaudited consolidated condensed interim financial statements presented in U.S. dollars and prepared in accordance with IFRS Accounting Standards as issued by the International Accounting Standard Board and adopted by the European Union, or IFRS. Additionally, this press release includes non-IFRS alternative performance measures i.e., EBITDA, Free Cash Flow, Net cash / debt and Operating working capital days. See exhibit I for more details on these alternative performance measures.

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Tenaris (TS) have what it takes?

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Tenaris (TS) have what it takes?

Toronto, Ontario – TheNewswire - July 15, 2026 – NeuroThera Labs Inc. (TSXV: NTLX) (the " Company " or " NeuroThera "), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC), today announced the initiation of its Phase IIb clinical trial site at  Hannover Medical School, Hanover (“MHH”), Germany, for SCI-110, its proprietary cannabinoid-based treatment candidate for Tourette Syndrome (TS) in adults.   The trial, which previously received regulatory clearance from Germany's Federal Institute for Drugs and Medical Devices and MHH's ethics committee , is now advancing towards the next stage at Hannover Medical School, one of the key clinical sites of the study. SCI-110 combines dronabinol with the endocannabinoid-like palmitoylethanolamide in an innovative one dosage form designed to reduce tics and comorbid symptoms in adults with TS while minimizing side effects.

PARAMARIBO, Suriname, June 30, 2026 (GLOBE NEWSWIRE) -- Tenaris announced today that operations have started at its new service center in Suriname, built to support the GranMorgu project, the country's first major offshore development, operated by TotalEnergies, with APA Corporation and Staatsolie Maatschappij Suriname N.V. as partners. Located in Paramaribo, the center will provide integrated services for offshore operations, reinforcing Tenaris's commitment to the development of Suriname's energy sector.

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Tenaris (TS) have what it takes?

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Tenaris (TS) have what it takes?